- In September 2024, Pfizer showcased its comprehensive oncology portfolio at the ESMO Congress, presenting over 50 company-sponsored abstracts. These included 10 oral and mini-oral presentations highlighting early results and next-generation candidates. This emphasizes Pfizer’s commitment to innovation in oncology, focusing on combination therapies and groundbreaking approaches to cancer treatment, which may significantly enhance therapeutic options for patients worldwide
- In September 2024, Merck announced positive Phase 3 trial results for GARDASIL 9 in Japanese males, showcasing its efficacy in reducing HPV-related anogenital persistent infections. This milestone highlights the vaccine’s global applicability and underscores Merck’s dedication to expanding prevention options for HPV-related diseases, fortifying its leadership in the HPV vaccine market
- In May 2024, Roche gained FDA approval for its HPV self-collection solution, facilitating greater access to cervical cancer screenings. This innovation aligns with the WHO’s initiative to eliminate cervical cancer by 2030, empowering women with easier testing options and advancing global public health goals by addressing a critical barrier to early detection
- In March 2024, Merck & Co., Inc. is set to launch clinical trials for a novel investigational multi-valent HPV vaccine and a single-dose GARDASIL 9 regimen. These developments aim to enhance vaccine efficacy and accessibility, potentially reshaping HPV prevention strategies while bolstering Merck’s leadership in combating HPV-related diseases globally
- In September 2023, INOVIO Pharmaceuticals received breakthrough therapy designation from the U.S. FDA for INO-3107, an investigational DNA medicine targeting HPV-6 and HPV-11. Designed to provoke a targeted T-cell response, INO-3107 offers promise for treating recurrent respiratory papillomatosis and other HPV-related conditions, potentially broadening the scope of therapeutic HPV solutions
- In 2023, The FDA approved the first vaccine for preventing cervical cancer caused by HPV, a breakthrough expected to reduce cervical cancer cases by up to 90%. This landmark approval marks a pivotal advancement in public health, offering robust prevention and paving the way for widespread adoption in global HPV immunization programs
Frequently Asked Questions
The market is segmented based on Global Human Papillomavirus (HPV) Associated Disorders Market Segmentation, By Indication (Cervical Intraepithelial Neoplasia (CIN), Cervical Cancer, Anal Intraepithelial Neoplasia (AIN), Anal Cancer, Genital Warts, Others), Therapy (Medication, Surgery, and Treatment), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Vaccine Type (HPV9 Vaccine, HPV4 Vaccine, and HPV2 Vaccine) – Industry Trends and Forecast to 2032
.
The Global Hpv Associated Disorders Market size was valued at USD 20.51 USD Billion in 2024.
The Global Hpv Associated Disorders Market is projected to grow at a CAGR of 4.62% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
